A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

NCT05519839 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1579

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Influenza

Interventions

DRUG: qNIV Vaccine with Matrix-M Adjuvant
DRUG: Influenza Vaccine
DRUG: CIC Vaccine with Matrix-M Adjuvant
OTHER: Placebo Comparator
DRUG: SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant

Sponsor

Novavax